Citation Impact
Citing Papers
Activation-Induced Cytidine Deaminase Accelerates Clonal Evolution in BCR-ABL1 –Driven B-Cell Lineage Acute Lymphoblastic Leukemia
2010
Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy
2015
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
KEAP1 and done? Targeting the NRF2 pathway with sulforaphane
2017
Astrocytes: biology and pathology
2009 Standout
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer
2016 StandoutNobel
Head and neck squamous cell carcinoma
2020 Standout
Combined autophagy and HDAC inhibition
2014
Gender medicine and oncology: report and consensus of an ESMO workshop
2019
MYC on the Path to Cancer
2012 Standout
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
2018
Glucosinolates and isothiocyanates in health and disease
2012
Nrf2-Keap1 signaling in oxidative and reductive stress
2018 Standout
A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells
2017
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
2014
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
2020
Marine natural products
1990 Standout
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
2020
Drug development from marine natural products
2008 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Cancer stem cells revisited
2017 Standout
Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer
2007
Machine Learning methods for Quantitative Radiomic Biomarkers
2015 Standout
Pancreatic Adenocarcinoma
2014 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Hydrophilic interaction chromatography
2006 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Breaking the DNA damage response to improve cervical cancer treatment
2015
Strategies to Inhibit Myc and Their Clinical Applicability
2017
Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane
2015
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Cancer epigenetics reaches mainstream oncology
2011
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Emerging Biological Principles of Metastasis
2017 Standout
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
2013
Non-coding RNAs in human disease
2011 Standout
Analysis of anticancer drugs: A review
2011 Standout
Targeting metastasis
2016
DNA repair dysregulation from cancer driver to therapeutic target
2012
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
2013
Recent agents targeting HIF‐1α for cancer therapy
2012
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Targeting autophagy in cancer
2017 Standout
A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics
2020 StandoutNobel
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
2019 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Translational research in oncology—10 years of progress and future prospects
2014
Targeted Therapy for Malignant Glioma Patients: Lessons Learned and the Road Ahead
2009
The AID Dilemma
2012 StandoutNobel
The PI3K Pathway in Human Disease
2017 Standout
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
2015
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
Targeting autophagy during cancer therapy to improve clinical outcomes
2011
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane
2012
Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids
2015
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Management of glioblastoma: State of the art and future directions
2020 Standout
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Practical Approach to Triple-Negative Breast Cancer
2017
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Biomedical applications of copper ionophores
2020
Trabectedin (Et-743): Evaluation of Its Use In Advanced Soft-Tissue Sarcoma
2007
Comprehensive Review in Current Developments of Imidazole-Based Medicinal Chemistry
2013
Chemical Synthesis of Homogeneous Human Glycosyl-interferon-β That Exhibits Potent Antitumor Activity in Vivo
2012
Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort
2015
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
2013
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
2015
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Cellular and cell-free studies of catalytic DNA cleavage by ruthenium polypyridyl complexes containing redox-active intercalating ligands
2017
The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies
2021 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Gene targets of sulforaphane in head and neck squamous cell carcinoma
2019
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Expanding the scope of N → S acyl transfer in native peptide sequences
2015 StandoutNobel
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal
2014 Standout
Cultivation, Genetic, Ethnopharmacology, Phytochemistry and Pharmacology of Moringa oleifera Leaves: An Overview
2015 Standout
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Drug Resistance in Cancer: An Overview
2014 Standout
Stabilized sulforaphane for clinical use: Phytochemical delivery efficiency
2016
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
2013
Works of Jan H. Beumer being referenced
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer
2016
ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
2014
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
2012
Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
2013
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
2013
Liquid chromatography–tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776
2010
Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
2005
Chemopreventative Potential of the Cruciferous Vegetable Constituent Phenethyl Isothiocyanate in a Mouse Model of Prostate Cancer
2011
A liquid chromatography–electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum
2006
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis
2012
Quantitation of 5‐fluorouracil (5‐FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry
2007
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)
2007
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
2009
Role of PARP Inhibitors in Cancer Biology and Therapy
2012
Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection
2005
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
2015
Effect of antacid on imatinib absorption
2008
Hepatotoxicity and metabolism of trabectedin: a literature review
2005
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation
2018
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
2012
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
2013
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice
2007
In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization
2010
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
2007
Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).
2014
A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).
2015
Sulforaphane Inhibits Prostate Carcinogenesis and Pulmonary Metastasis in TRAMP Mice in Association with Increased Cytotoxicity of Natural Killer Cells
2009
A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.
2012
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
2018
Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: In Vitro Support for a Novel Drug Repurposing Strategy
2019
Dose-response evaluation of brocolli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplastic nevi (A/DN).
2016
ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage
2013
Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine
2008
Disposition of Imatinib and Its Metabolite CGP74588 in a Patient with Chronic Myelogenous Leukemia and Short‐Bowel Syndrome
2006
Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).
2014